Vyleesi and Bremelanotide

PT-141 Side Effects: What the Data Shows

13 min read|March 25, 2026

Vyleesi and Bremelanotide

40% nausea

Nausea occurred in 40% of bremelanotide-treated patients in phase 3 trials, making it the most common side effect. It was the leading cause of treatment discontinuation.

Clayton et al., Journal of Women's Health, 2022

View as image

Bremelanotide (marketed as Vyleesi, originally developed as PT-141) is an FDA-approved melanocortin receptor agonist for premenopausal women with hypoactive sexual desire disorder. It works through a fundamentally different mechanism than PDE5 inhibitors, acting on melanocortin-4 receptors in the central nervous system rather than on blood flow. That central mechanism is also what produces its side effect profile: nausea, blood pressure changes, and skin darkening all trace back to melanocortin receptor activation in the brain and periphery.

Vyleesi's clinical evidence for sexual desire is covered in the pillar article. This article focuses specifically on what the safety data shows, drawn from the phase 3 RECONNECT trials, the integrated safety analysis, and independent re-analyses of the clinical program.

Key Takeaways

Nausea occurred in 40% of bremelanotide-treated women versus 1.3% with placebo in phase 3 trials; it was the most common reason for discontinuation but decreased after the first dose (Clayton et al., 2022)
Bremelanotide causes a transient increase in systolic blood pressure averaging 6 mmHg and diastolic of 3 mmHg, peaking 2-4 hours post-dose and resolving within 12 hours; it is contraindicated in uncontrolled hypertension (White et al., 2017)
Focal hyperpigmentation (skin darkening) of the face, gums, and breasts was reported in 1% of clinical trial participants; the FDA label warns it may not resolve after stopping treatment (Dhillon et al., 2019)
Long-term safety data over 52 weeks showed no new safety signals beyond those identified in the 24-week core studies (Simon et al., 2019)
Independent re-analysis questioned whether the magnitude of sexual desire improvement justifies the side effect burden, noting that 72.7% of protocol-listed outcomes were not reported in the primary publication (Spielmans et al., 2021)
The FDA approved bremelanotide with restrictions: no more than one dose per 24 hours and no more than 8 doses per month

Nausea: the dominant side effect

Nausea is bremelanotide's most common adverse effect and the primary reason patients discontinue treatment.

Clayton et al. (2022) published the integrated safety analysis across the entire bremelanotide clinical development program. Nausea occurred in 40.0% of bremelanotide-treated patients versus 1.3% with placebo. The nausea is mechanistically linked to bremelanotide's activation of melanocortin receptors in the area postrema, the same brainstem region that mediates chemotherapy-induced nausea.^[1]

There is a critical pattern: nausea severity decreases with subsequent doses. The first injection produces the worst nausea. By the third and fourth doses, most patients who continue treatment report substantially less nausea. This is thought to reflect receptor desensitization or habituation of the emetic pathway.

Kingsberg et al. (2019) reported the phase 3 RECONNECT trial data: in the two identical randomized, double-blind trials, nausea was listed as the adverse event leading to study discontinuation in a meaningful proportion of the bremelanotide group. Despite this, the majority of patients who experienced nausea elected to continue treatment.^[2]

Vomiting, a more severe gastrointestinal effect, occurred in approximately 4.8% of treated patients. Mayer and Lynch (2020) noted that nausea onset typically occurs 30-60 minutes after injection and lasts approximately 2 hours, though some patients report longer durations.^[3]

Blood pressure effects

Melanocortin-4 receptor activation increases sympathetic nervous system activity, which raises blood pressure. This is a class effect of melanocortin agonists, not unique to bremelanotide.

White et al. (2017) conducted a dedicated ambulatory blood pressure monitoring study of bremelanotide. The key findings: bremelanotide produced a transient increase in systolic blood pressure averaging 6 mmHg and diastolic blood pressure averaging 3 mmHg. The increase peaked 2-4 hours after subcutaneous injection and resolved within 12 hours. Heart rate decreased by an average of 5-6 beats per minute, a reflex response to the blood pressure increase.^[4]

The clinical significance of a transient 6 mmHg systolic increase is debatable in normotensive individuals. For patients with pre-existing uncontrolled hypertension or cardiovascular disease, this temporary increase could be clinically meaningful. The FDA label contraindications reflect this concern: bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease.

Dhillon and Keam (2019) noted that the blood pressure effect is why bremelanotide was restricted to on-demand subcutaneous injection rather than developed as a daily oral medication. The transient, dose-dependent nature of the blood pressure response makes occasional use safer than chronic daily exposure.^[5]

The early intranasal formulation of PT-141, tested by Diamond et al. (2004), was abandoned partly because intranasal delivery produced less predictable blood pressure responses. The subcutaneous route provided more consistent pharmacokinetics and more manageable hemodynamic effects.^[6]

Skin darkening (hyperpigmentation)

Bremelanotide activates melanocortin-1 receptors (MC1R) on melanocytes in addition to its target melanocortin-4 receptors in the brain. MC1R activation stimulates melanin production, the same pathway exploited by melanotan II for cosmetic tanning.

In the phase 3 trials, focal hyperpigmentation was reported in approximately 1% of treated participants. The affected areas were characteristically the face, gums, and breasts. The FDA label contains a specific warning that this darkening may not resolve upon discontinuation of treatment.^[5]

The hyperpigmentation risk increases with frequency of use, which is one reason the FDA restricted bremelanotide to no more than 8 doses per month. Clayton et al. (2022) confirmed that in the integrated safety database, pigmentation changes were uncommon at recommended dosing frequencies but became more likely with higher cumulative exposure.^[1]

This effect is distinct from the widespread tanning produced by melanotan II (a related melanocortin peptide sold on the black market). Bremelanotide's MC1R activation is less potent than melanotan II's, and the approved dosing limits prevent the cumulative melanocyte stimulation that produces full-body pigmentation changes. Nelson et al. (2012) documented severe toxicity from melanotan II injection, including rhabdomyolysis, illustrating the risks of unregulated melanocortin peptide use that bremelanotide's controlled dosing was designed to avoid.^[7]

Other reported side effects

The integrated safety analysis documented additional adverse events at lower frequencies:^[1]

Flushing: 20.3% (related to vasodilation from melanocortin activation)
Injection site reactions: 13.2%
Headache: 11.3%
Fatigue: 3.2%
Hot flashes: 2.7%
Paresthesia (tingling): 2.6%
Dizziness: 2.2%
Nasal congestion: 2.1%

Flushing is the second most common side effect after nausea. Like nausea, it is mechanistically linked to melanocortin receptor activation and tends to diminish with repeated dosing.

Long-term safety

Simon et al. (2019) reported long-term safety data from patients who continued bremelanotide for up to 52 weeks in the open-label extension of the RECONNECT trials. No new safety signals emerged beyond those identified in the 24-week core studies. Blood pressure effects remained transient and did not show cumulative worsening. Hyperpigmentation events remained infrequent at recommended dosing. No serious cardiovascular events were attributed to bremelanotide.^[8]

The long-term data is reassuring but limited. The open-label extension enrolled only patients who tolerated the drug during the core trial (a selection bias that excludes the most side-effect-prone individuals). Real-world long-term safety data from routine clinical use is still accumulating.

Early PT-141 pharmacology data

Before bremelanotide was developed for female sexual dysfunction, it was studied as PT-141 for male erectile dysfunction.

Rosen et al. (2004) evaluated subcutaneous PT-141 in healthy male subjects and men with erectile dysfunction who had inadequate response to sildenafil. The safety profile was consistent with later female studies: nausea was the most common adverse event, blood pressure showed transient increases, and no serious adverse events occurred. Erectile responses were observed through a central mechanism distinct from PDE5 inhibition.^[9]

This early male data is relevant because it established that the side effect profile is consistent across sexes. The nausea, blood pressure, and flushing effects are not sex-specific; they are inherent to melanocortin receptor activation. PT-141 for male erectile dysfunction covers the male-specific research in detail.

Independent critiques of the safety-benefit balance

Spielmans (2021) published a re-analysis of the phase 3 RECONNECT trials, raising concerns about selective outcome reporting. The analysis found that 72.7% of protocol-listed outcomes were not reported in the primary publication by Kingsberg et al. Among the reported outcomes, the effect sizes for sexual desire improvement were small, leading the author to question whether the magnitude of benefit justified the side effect burden, particularly the 40% nausea rate.^[10]

Spielmans (2024) followed up with a broader critique of bremelanotide's efficacy outcomes, arguing that the patient-reported measures used in the trials may not have been adequately validated and that the clinical meaningfulness of the observed changes remained questionable.^[11]

These critiques do not dispute the safety data itself but argue that the side effect burden should be weighed against a modest efficacy signal. The FDA approval included the benefit-risk assessment that for premenopausal women with genuine HSDD, even modest improvement in sexual desire represents meaningful clinical benefit given the absence of many treatment alternatives.

FDA-imposed restrictions

The FDA approved bremelanotide with several restrictions that directly reflect its side effect profile:

Dose frequency limit: No more than 1 dose per 24 hours, and no more than 8 doses per month. This limits cumulative melanocortin receptor exposure, reducing hyperpigmentation risk and cumulative cardiovascular stress.
Contraindication in uncontrolled hypertension: The transient blood pressure increase makes bremelanotide inappropriate for patients whose blood pressure is not already controlled.
Contraindication with naltrexone: Bremelanotide may reduce the efficacy of naltrexone, used for opioid dependence and alcohol use disorder. This interaction is particularly relevant because opioid and melanocortin systems overlap in the hypothalamus and brainstem, and melanocortin receptor activation can modulate endogenous opioid signaling.
Self-injection requirement: Bremelanotide is administered by subcutaneous autoinjector at least 45 minutes before anticipated sexual activity. The injection itself is a barrier for some patients, though the autoinjector device is designed to be comparable in ease of use to insulin pens.

Understanding how bremelanotide works at the CNS level provides context for why these side effects occur. The melanocortin system is involved in appetite regulation, autonomic function, and pigmentation in addition to sexual function, and activating it inevitably produces effects beyond the intended target. How PT-141 compares mechanistically to PDE5 inhibitors like Viagra is a separate but related question.

The Bottom Line

Bremelanotide's side effect profile is driven by melanocortin receptor activation beyond its CNS target. Nausea (40%), flushing (20%), and transient blood pressure elevation (average 6 mmHg systolic) are the most common effects. Skin darkening is uncommon at approved dosing but may not be reversible. Long-term data over 52 weeks showed no new safety signals. Independent re-analyses question whether the modest efficacy signal justifies the side effect burden. The FDA addressed these concerns with dose frequency limits and cardiovascular contraindications.

Frequently Asked Questions

The most common side effect is nausea, occurring in 40% of patients in phase 3 trials compared to 1.3% with placebo (Clayton et al., 2022). Flushing affects 20.3%, injection site reactions 13.2%, and headache 11.3%. Nausea is typically worst with the first dose and decreases with subsequent injections. It usually begins 30-60 minutes after injection and lasts approximately 2 hours. Vomiting occurs in about 4.8% of patients.

Yes, but transiently. White et al. (2017) used ambulatory blood pressure monitoring and found that bremelanotide raises systolic blood pressure by an average of 6 mmHg and diastolic by 3 mmHg, peaking 2-4 hours after injection and resolving within 12 hours. Heart rate decreases by 5-6 beats per minute as a reflex response. This is why bremelanotide is contraindicated in patients with uncontrolled hypertension or cardiovascular disease.

Focal hyperpigmentation of the face, gums, and breasts was reported in approximately 1% of clinical trial participants. The FDA label warns that this skin darkening may not resolve after stopping treatment (Dhillon et al., 2019). The risk increases with frequency of use, which is why the FDA limits bremelanotide to no more than 8 doses per month. The effect results from melanocortin-1 receptor activation on melanocytes, stimulating melanin production.

Simon et al. (2019) reported long-term safety data over 52 weeks with no new safety signals beyond those identified in the initial 24-week studies. Blood pressure effects remained transient and did not worsen cumulatively. However, the long-term data comes from patients who tolerated the drug during the initial trial, excluding those most prone to side effects. The FDA approved bremelanotide for on-demand use with frequency limits, not continuous daily therapy.

Both PT-141 and GLP-1 agonists cause nausea through central nervous system mechanisms, but the patterns differ. PT-141 nausea occurs acutely after each dose and typically lasts about 2 hours. GLP-1 agonist nausea can persist for days to weeks during dose titration. PT-141 nausea tends to improve after the first few doses, while GLP-1 nausea improves over weeks of continued use. The 40% nausea rate with PT-141 is comparable to or higher than most GLP-1 agonists at their starting doses.

The 8-dose monthly limit reflects two safety concerns. First, cumulative melanocortin-1 receptor activation stimulates melanin production, and higher-frequency dosing increases the risk of potentially irreversible skin darkening. Second, limiting dose frequency reduces cumulative cardiovascular exposure from the transient blood pressure increases that occur with each dose. The FDA determined that on-demand use at this frequency maintained an acceptable benefit-risk profile.